Company Overview and News
If it wasn't before, it is definitely a slump now. The National Association of Realtors (NAR) said today that the sales of existing homes across the US in September 2018 fell more than 3% seasonally-adjusted from August. At just 5.15 million (SAAR), that's the lowest volume in almost three years.
Good day, ladies and gentlemen, and welcome to the Glacier Bancorp Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, today's conference is being recorded.
WFC WFCNP GBCI SECB SYBJF FIIT
Ladies and gentlemen, thank you for standing by. Welcome to the Schlumberger Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Instructions will be given at that time. [Operator Instructions] As a reminder, today’s call is being recorded. I would now like to turn the conference over to our host, Vice President of Investor Relations, Mr.
WFC WFCNP SLB SCL SLB
(Reuters) - Iron ore producer Cleveland-Cliffs Inc Chief Executive Officer Lourenco Goncalves slammed Wall Street financial analysts on Friday, saying some of them were an “embarrassment” and did not understand his company’s business.
V.F. Corp.’s jeans business, which includes brands like Lee and Wrangler, slipped 7% in the second-quarter, signaling the impact of the Sears Holdings Corp. bankruptcy.
WFC WFCNP SHLD SHLDW
Good morning everyone, and welcome to the Citizens Financial Group Third Quarter 2018 Earnings Conference call. My name is Brad, and I’ll be your operator on the call today. Currently all participants are in a listen-only mode. Following the presentation, we will conduct a brief question-and-answer session. As a reminder, this conference is being recorded.
WFC WFCNP DB CFG CFIN CIWV
Filed Pursuant to Rule 424(b)(2) File No. 333-221324
Last week, I had the pleasure of addressing the Michigan Credit Union Economic Summit on the future of financial services. I discussed emergent themes in financial regulation as a result of new technologies, and their implications for the industry. Here are my remarks — I hope you find them informative.
If you have been looking for Large Cap Growth funds, a place to start could be Wells Fargo Premier Large Company Growth A (EKJAX - Free Report) . EKJAX possesses a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on nine forecasting factors like size, cost, and past performance.
Senator Elizabeth Warren pressed the extent of the power of her office as she insisted that the CEO of Wells Fargo & Co. (NYSE: WFC) be fired. Some of the points she made to the Federal Reserve are accurate, even if her opinion that she has leverage over such a decision is not.
ZURICH, Oct 19 (Reuters) - Ten years after a booming business with discretion-minded U.S. clients cost Swiss banks billions of dollars and put an end to Swiss banking secrecy, the world’s private banking hub is looking to reestablish ties with American customers.
WFC WFCNP MS
All things considered, it could have been worse. The S&P 500 could have closed at Wednesday’s low of 2,781.81, logging a 1% loss for the session, quelling any hopes for a rebound built on Monday’s big bounce. But the market snapped back at mid-day, closing the gap to a loss of only 0.03% yesterday.
WFC WFCNP M AMD CSX AA
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET